Latest Articles about PBE

Biotechnology ETF Investing 101 - ETF News And Commentary

Zacks Equity Research — Mon, 20 May 2013 19:03:46 Z

With ever-increasing health care spending and insatiable demand for new drugs, the biotechnology sector looks poised for good growth going forward. Furthermore, the U.S. biotech sector

Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for May 14, 2013

NASDAQ.com News — Mon, 13 May 2013 15:39:06 Z

Amgen Inc. ( AMGN ) will begin trading ex-dividend on May 14, 2013. A cash dividend payment of $0.47 per share is scheduled to be paid on June 07, 2013. Shareholders who purchased AMGN stock

Best ETFs In 2013: DBJP, Tesla-Fueled QCLN

Cinthia Murphy — Mon, 13 May 2013 15:00:00 Z

The First Trust Nasdaq Clean Edge Green Energy ETF (NasdaqGM:QCLN) is challenging the db X-trackers MSCI Japan Hedged Equity ETF (NYSEArca:DBJP) for first position in a tally of top-performing

Under The Hood: An Unheralded Biotech ETF

ETF Professor — Thu, 11 Apr 2013 21:53:01 Z

Another day, another set of fresh all-time highs for the major biotechnology ETFs . Biotech investors were treated to the same feat in late March , but as health care has continued to be a

Gilead Puts Biotech ETFs in Focus - ETF News And Commentary

Zacks Equity Research — Mon, 11 Mar 2013 19:10:39 Z

California-based Gilead Sciences ( GILD ) was in focus last week as it saw some encouraging clinical trial data on its HIV pill-TAF. This report pushed up GILD by about 4.5% last week and

Best/Worst Daily ETF Returns: PBE Rises 1.66%

Hannah Tool — Mon, 04 Mar 2013 21:00:00 Z

The PowerShares Dynamic Biotech & Genome Portfolio (NYSEArca:PBE) rose 1.66 percent on Friday, March 1, while the S&P 500 climbed 3.52 points, or 0.26 percent, to close at

Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for February 11, 2013

NASDAQ.com News — Thu, 07 Feb 2013 19:00:04 Z

Amgen Inc. ( AMGN ) will begin trading ex-dividend on February 11, 2013. A cash dividend payment of $0.47 per share is scheduled to be paid on March 07, 2013. Shareholders who purchased AMGN

4 Health Care ETFs Your Broker Forgot to Mention

ETF Professor — Tue, 08 Jan 2013 01:52:42 Z

When it comes to health care ETFs , there are plenty for investors to choose from. How well acquainted folks are with all of their options in this sector is another story. Sure, it is safe to

Biotech ETFs: Not All Equal

Devin Riley — Wed, 01 Aug 2012 20:25:50 Z

Biotech ETFs have had a banner year, earning some investors returns north of 30 percent since January. I say "some investors" because, it turns out, not all biotech ETFs are created

Arena Approval Boosts Biotech ETFs (ARNA, IBB, XBI)

Benzinga — Wed, 27 Jun 2012 22:41:06 Z

News that the Food & Drug Administration has approved Arena Pharmaceuticals' (NASDAQ: ARNA ) weight-loss pill Lorcaserin is proving to be a boon for some biotech ETFs. Lorcaserin

The Definitive Biotech ETF Guide (IBB, XBI, FBT)

Benzinga — Mon, 21 May 2012 21:35:37 Z

Lifted by new drug approvals along with increased mergers and acquisitions activity and a churning rumor mill to that effect, biotechnology stocks have been stellar performers in 2012.

Fundamental ETFs Throw their Weights Around

Will McClatchy — Mon, 21 Mar 2011 13:00:00 Z

Most ETFs and mutual funds weight companies they holding by market capitalization. The market's collective judgment of the worth of each security, however, is not the only way to weight

Why Health Care ETFs May Be In the Clear

tlydon@globaltrend.com (Tom Lydon) — Thu, 11 Nov 2010 00:00:49 Z

After the Democrats lost some seats in the mid-term elections, you might be wondering whether health care revenue and exchange traded funds (ETFs) will be affected by the shift. Some don't

Health Care Under Scrutiny

ETFzone Staff — Sun, 07 Nov 2010 15:00:00 Z

Health care followed the roller coaster which most equities rode in 2010, and towards the end investors were smiling. But a decisive victory mid-term election by Republicans begs the

McCall’s Call: The Cancer-Cure Biotech ETFs

Matthew D. McCall — Thu, 17 Jun 2010 19:34:39 Z

The future growth of the biotechnology and pharmaceutical sectors will hinge largely on advances made in cancer treatment, and biotech firms in particular look likely to reap the benefits of